Shield's Feraccru misses in Phase III for anemia

Shield Therapeutics plc (LSE:STX) reported that Feraccru ferric maltol missed the primary endpoint in the U.S. Phase III AEGIS-CKD trial to treat iron deficiency anemia (IDA) in patients with non-dialysis-dependent chronic kidney disease (CKD).

On the 168-patient trial's primary endpoint, twice-daily oral 30 mg Feraccru failed to significantly improve hemoglobin levels from baseline to week 16 vs. placebo (0.45 vs. 0.15 g/dL, p=0.1686). Secondary endpoints in the trial include the proportion of patients that achieve an increase in hemoglobin of ≥1, ≥2 and ≥11 g/dL at week 16, change from baseline in hemoglobin levels at week eight, change in iron parameters and safety...